mark leschly rho ventures llc profile  biography  bloomberg feedback mark leschly managing partner rho ventures llc career history managing partner rho capital partners inc present managing partner rho ventures llc present chairman senomyx inc  consultant mckinsey  co inc  general partner healthcare ventures llc former mckinsey  co inc former show more website wwwrhoventurescom corporate information address carnegie hall tower  west th st rd floor new york ny 00 united states phone  fax  web url wwwrhoventurescom from the web personal information education harvard college bachelors degree stanford graduate school of business mba memberships board memberships ngm biopharmaceuticals inc board member present medical present value inc board member present broadlogic network technologies inc board member present coulomb technologies inc board member present chacha search inc board member present national venture capital association board member present tapjoy inc board member present anacor pharmaceuticals inc board member present verenium corp board member 00 senomyx inc chairman  diversa corp board member 0 anacor pharmaceuticals inc chairman  versicor inc board member  senomyx inc board member 0 archemix corp board member former gloucester pharmaceuticals board member former inotek pharmaceuticals corp board member former memory pharmaceuticals corp board member former broadlogic inc board member former ripe digital entertainment board member former orqis medical corp board member former orametrix inc board member former slacker inc board member former tolerrx inc board member former vanda pharmaceuticals inc board member former vicuron pharmaceuticals inc board member former sitv board member former tercica inc board member unknown nitromed inc board member unknown show more other memberships national venture capital association board member sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data mark leschly  managing partner contact us home rho rho canada ventures rho fund investors rho acceleration    follow us search rho ventures investing approachrho valuesfast facts overviewpartnersprincipalschief financial officergeneral counsel key successesinvestmentscase studiesenergy technologyhealthcareit  communicationsnew mediajobs  rho companies team  partners  mark leschly investment focus areas new media healthcare information technology current investments chargepoint fuse media mandalay sports media ngm orametrix slacker tapjoy techstyle select past investments anacor nasdaq anac sold to pfizer aquesys sold to allergan broadlogic sold to broadcom dendreon ipo diversa ipo merged with celunol to become verenium gloucester acquired by celgene corporation human genome sciences ipo leukosite acquired by millennium pharmaceuticals medimmune ipo acquired by astrazeneca memory ipo mpv acquired by experian nitromed ipo pht sold to ert senomyx ipo tercica ipo acquired by ipsen vanda ipo vicuron ipo acquired by pfizer d pharmaceuticals ipo acquired by johnson  johnson click here to see all rho ventures investments mark leschly managing partner  mark leschly is a managing partner of rho capital partners and rho ventures a member of the investment committee of rho fund investors and established rho’s west coast office with  years of experience in private equity and venture capital mark is an experienced and seasoned investor firmly committed to finding and optimizing ways to support technology company ceos and their teams build compelling highgrowth businesses mark started his investment career with a focus in healthcare life sciences medical devices and healthcare information technology and for more than a decade has broadened his focus to include the digital mediainternet and mobile sectors he heads rhos west coast investments and is a leader of the firms new media and healthcare practices prior to joining rho he spent five years at healthcare ventures as general partner and had several years of management strategic consulting experience at mckinsey  company mark is a former touring professional tennis player previously selected to the danish davis cup team he received an mba from stanford university’s graduate school of business and a ba from harvard university he serves on the board of the directors of the national venture capital association overview partners habib kairouz mark leschly doug mccormick joshua ruch martin vogelbaum patrick wack principals chief financial officer general counsel copyright   rho ventures all rights reserved mark leschly  atherton ca  intelius sign in we found mark leschly in atherton ca mark leschly intelius found that mark leschly is a male between 0 and 0 years old from atherton ca we have connected them to  addresses  phones and  relatives or associates get report now age mark leschly is in his 0s mark has lived in atherton ca hopewell nj palo alto ca marks relatives nick leschly jan leschly lotte leschly stig leschly mark leschly gendermale professional status board member at nephrogenex inc get report now want to know more about mark get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about mark or use our people search engine to find others get background check on mark leschly get a criminal check on mark leschly get a public record report on mark leschly get a people search report on mark leschly mark leschlys contact information known cities lived in find out where mark leschly has lived as well as mark leschlys phone numbers and email addresses mark leschly has lived in  states california address for mark leschly  o g a atherton ca has lived in atherton ca hopewell nj get full address report phone numbers associated with mark leschly 0   atherton ca 0   princeton nj    palo alto ca get full phone report email addresses associated with mark leschly mycom get email report mark leschlys professional information information regarding mark leschlys professional history find out previous places mark leschly has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act mark leschly has worked at  place company nephrogenex inc title board member mark leschlys experience title board member company nephrogenex inc job details company size less than  mil additional professional information on mark leschly see mark leschlys linkedin profile mark leschlys social network and potential email matches find out potential social network profiles and potential email usernamed for mark leschly mark leschlys known social networks and potential email matches find all of mark leschlys social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches mark leschly username matches markleschly leschlymark markleschly leschlymark markleschly leschlymark markleschly leschlymark mleschly popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches m leschly intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here 0  forbidden access is denied server error 0  forbidden access is denied you do not have permission to view this directory or page using the credentials that you supplied mark leschly  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors mark leschly check out list of companies and businesses related to mark leschly find out mark leschly address and contact details view other people related to mark leschly  coworkers colleagues companions etc address  west th street rd floor new york 00 ny companies related to mark leschly cikcompany namepositioncompany address00000bluefly inc west th st new york 00000inotek pharmaceuticals corp hartwell ave nd floor lexington 000reachlocal inc0 oxnard street suite 00 woodland hills 0000nephrogenex incpo box 00 jamison  mark leschly on the web persons related to mark leschly  bluefly incnamepositioncityriad m abrahamsdirector new yorkriad m abrahamsdirector new yorkriad m abrahamsdirector new yorklee s ainslie iiinew yorklee s ainslie iiinew yorkrussell andrewnew yorkjackson annnew yorkplesner anthonynew yorkerdos barrynew yorkpatrick barrycoo and cfo patrick barrycoo and cfo new yorkpatrick barrycoo  cfo new yorkmatson bradfordnew yorkmario ciampidirector new yorkmario ciampidirector new yorkmario ciampidirector greenwichdeborah arpert claynew yorkjanke davidnew yorkwassong davidnew yorkseegal denisenew yorkscott erdmansvp of merchandising new yorkbarry erdosnew yorkbarry erdosdirector new yorkbarry erdosdirector new yorkjosephine esquiveldirector new yorkjames g gallaghernew yorkmichael jonathan grossdirector new yorkkairouz habibnew yorkmonica halpertnew yorkmichael helfanddirector new yorkann jacksondirector new yorkann jacksondirector new yorkdavid alexis jankedirector new yorkdavid alexis jankedirector new yorkkara b jennychief financial officer new yorkpark josephnew yorkhabib kairouzdirector new yorkhabib kairouznew yorkhabib kairouzdirector new yorkalan kanedirector new yorkalan kanedirector alan kanedirector new yorkjenny karanew yorkjenny karanew yorkmartin j keane iiisvp of ecommerce new yorkmark leschlynew yorkmark leschlynew yorkciampi marionew yorkclampi marionew yorkkeane martinnew yorkmiller martinnew yorkmiller martinnew yorkbradford matsonchief marketing officer new yorkbradford matsonchief marketing officer new yorkmaverick capital ltd0 owner dallasmaverick capital ltd0 owner dallasmaverick capital management llcdallasmaverick capital management llcdallasmaverick fund ii ltddallasmaverick fund ii ltddallaxmaverick fund ldcdallasmaverick fund ldcdallasmaverick fund usa ltddallaschristopher g mccannnew yorkchristopher g mccanndirector new yorkchristopher g mccanndirector new yorkpaynergregor melissanew yorkhelfand michaelnew yorkmartin h millerdirector new yorkmartin h millerdirector new yorkmartin h millerdirector new yorkjonathan b morrisnew yorkneal moszkowskidirector new yorkneal moszkowskidirector new yorkneal moszkowskidirector new yorkneal moszkowskidirector new yorkneal moszkowskidirector new yorkmoszkowski nealnew yorkjoseph parkchief executive officer new yorkmelissa paynermelissa paynerceo and president new yorkmelissa paynerchief executive officer new yorkmelissa paynerchief executive officer new yorkmelissa paynerchief executive officer new yorkmelissa paynerchief executive officer new yorkmelissa paynerchief executive officer new yorkanthony plesnerdirector new yorkprentice capital management lp0 owner new yorkprentice capital management lp0 owner greenwichqih management investor lpnew yorkqih management investor lpqih management investor lpqih management investor lpnew yorkqih management llcnew yorkqih management llcqih management llcnew yorkindustrial partners ldc et al quantum0 owner netherlands antillesindustrial partners ldc et al quantum0 owner willemstad curacaoindustrial partners ldc et al quantum0 owner antillesindustrial partners ldc et al quantum0 owner netherlandsindustrial partners ldc et al quantum0 owner netherlands antillesindustrial partners ldc et al quantum0 owner willemstad curacaoindustrial partners ldc et al quantum0 owner curacaoalexandre s rafaldirector new yorkrho capital partners llcnew yorkrho ventues vi lpnew yorkrho ventures vi lpdirector new yorkrmv vi llcnew yorkjoshua ruchnew yorkandrew russellnew yorkandrew russelldirector new yorkdenise seegaldirector new yorke kenneth seiffchairman and ceo new yorke kenneth seiff0 owner new yorksfm domestic investments llc0 owner new yorksoros fund management llcnew yorkgeorge soros0 owner new yorkgeorge soros0 owner new yorkgeorge soros0 owner new yorkgeorge soros0 owner new yorkrobert g stevensdirector new yorkdavid wassongdirector new yorkdavid wassongdirector new yorkdavid wassongdirector new yorkdavid wassongdirector new york new yorkdavid wassongdirector new yorkdavid wassongdirector new yorkdavid wassongnew yorklawrence j zigerellidirector new yorkmichael zimmermannew yorkmichael zimmermangreenwichmichael zimmermannew yorkpersons related to mark leschly  inotek pharmaceuticals corpnamepositioncityjerry karabelas phd argerislexingtonjerry karabelas phd argerislexingtonsaran atullexingtontimothy j barberichdirector concordrudolph baumgartnersee remarks lexingtoncarsten boessdirector cheshirecare capital ii llc0 owner princetoncare capital iii llcprincetoncare capital investments ii lpprincetoncare capital investments iii lpprincetoncare capital offshore investments ii lpprincetoncare capital offshore investments iii lpprincetonj martin carrolldirector ridgefielddevon park associates lp0 owner waynedevon park associates llcwaynedevon park bioventures lp0 owner wayneittai hareldirector lexingtonpaul g howesdirector paul g howeslexingtonharel ittailexingtonharel ittailexingtonham james iiilexingtonham james iiilexingtonleaman johnlexingtonleaman johnlexingtonhabib kairouznew yorkhabib kairouznew yorkdevang kantesaria0 owner lexingtonargeris n karabelasdirector san diegoargeris n karabelasprincetonmark leschlynew yorkmark leschlynew yorkclarence patrick machadodirector san franciscoleflore phd maggielexingtonvogelbaum martinlexingtonvogelbaum martinlexingtonwilliam k mcvicarsee remarks lexingtonmedimmune ventures inc0 owner gaithersburgloberg phd michaellexingtonloberg phd michaellexingtonhowes paullexingtonhowes paullexingtonisai peimerdirector san diegoisai peimerbethesdagary m phillipsdirector rochesterpitango gc capital holdings ltdherzliyapitango vc fund iv lpherzliyapitango venture capital fund iv lppalo altopitango venture capital fund iv lpherzliyapitango venture capital principals fund iv lp0 owner palo altopitango venture capital principals fund iv lpherzliyacapital partners verwaltungs gmbh rhonew yorkcapital partners verwaltungs gmbh rhonew yorkrho management ventures iv llcnew yorkrho management ventures iv llcnew yorkrho ventures iva lpnew yorkrho ventures iv gmbh  co beteiligungs kgnew yorkrho ventures iv gmbh  co beteiligungs kgnew yorkrho ventures iv holdings llc0 owner new yorkrho ventures iv lpnew yorkrho ventures iv lpnew yorkrho ventures iv qp lp0 owner new yorkrho ventures iv qp lpnew yorkdale rittervice president finance lexingtondale ritterlexingtonjoshua ruchnew yorkjoshua ruchnew yorkbaumgartner md rudolflexingtonbaumgartner md rudolflexingtondavid p southwellpresident and ceo concorddavid p southwelllexingtonrichard n spiveydirector lexingtonmartin vogelbaumdirector new yorkmartin vogelbaumnew yorkmcvicar phd williamlexingtonmcvicar phd williamlexingtonpersons related to mark leschly  reachlocal incnamepositioncitywergeles adamwoodland hillswergeles adamwoodland hillssalzman alanwoodland hillssalzman alanwoodland hillsavtzim llc0 owner las vegaskristopher bartonchief product officer woodland hillsdavid carlickdirector woodland hillsdavid carlickdirector woodland hillspowell chriswoodland hillsjoshua clamanpresident woodland hillscarlick davidwoodland hillscarlick davidwoodland hillsdavid daywoodland hillsdavid daysvp corp controller  cao woodland hillsflora daniel e dellasvp chief accounting officer woodland hillsrobert r b dykessan joserobert r b dykesdirector woodland hillsrobert r b dykesdirector woodland hillsthompson edwarddirector san joseshamia gadiawoodland hillsgalleon special opportunities master fund spc ltdgalleon crossover portfolinew yorkgalleon special opportunities master fund spc ltdgalleon crossover portfolinew yorkgalleon special opportunities master fund spc ltdgalleon crossover portfolinew yorkgalleon special opportunities master fund spc ltdgalleon crossover portfoli0 owner new yorkgannett co incmcleanjames f geigerdirector atlantajames f geigerdirector atlantajames f geigerdirector woodland hillsgordon family revocable trustlos angelesilana p gordonlos angeleszorik gordonpresident and ceo woodland hillszorik gordonpresident and ceo woodland hillszorik gordonchief executive officer woodland hillskalrouz habibwoodland hillskalrouz habibwoodland hillsjeffrey l haginschief technology officer woodland hillsjeffrey l haginschief technology officer woodland hillsjeffrey l haginschief technology officer woodland hillsthomas e haledirector san franciscothomas e haledirector woodland hillsnathan hankschief distribution officer woodland hillsnathan hankschief distribution officer woodland hillsnathan hankspresident woodland hillsnathan hankspresident woodland hillsalex hawkinsonchief product officer woodland hillsalex hawkinsonchief product officer woodland hillsgeiger jameswoodland hillsgeiger jameswoodland hillswhite jasonwoodland hillswhitt jasonwoodland hillsmazur johnwoodland hillshabib kairouzdirector new yorkhabib kairouzdirector woodland hillshabib kairouzdirector new yorkhabib kairouzdirector woodland hillshabib kairouzdirector woodland hillsmichael klinecoo  chief product officer woodland hillsmichael klinecoo woodland hillsmichael klinecso  pres of local commerce woodland hillslawrence m kutscherdirector short hillslawrence m kutscherdirector woodland hillsross landsbaumchief financial officer woodland hillsross landsbaumchief financial officer woodland hillsross landsbaumchief financial officer woodland hillsross landsbaumchief financial officer woodland hillsmark leschlynew yorkmark leschlynew yorkparas maniarchief strategy officer woodland hillsjohn mazurceo md reachlocal uk ltd woodland hillsjohn mazurceo md reachlocal uk ltd woodland hillsjohn mazurceo reachlocal europe woodland hillsjohn mazurwoodland hillskline michaelwoodland hillskline michaelwoodland hillshanks nathanwoodland hillshanks nathanwoodland hillschris powellsvp cor controller  cao woodland hillssteven r powerceo reachlocal australia woodland hillssteven r powerevp global sales operations woodland hillssteven r powerchief sales officer woodland hillsraptor merger sub incmcleanrho capital partners llcnew yorkrho ventures v affiliates llcnew yorkrho ventures v lp0 owner new yorkrmv v llcnew yorkdykes robertwoodland hillsdykes robertwoodland hillsspitz robertwoodland hillsspitz robertwoodland hillswright robertwoodland hillswright robertwoodland hillslandsbaum rosswoodland hillslandsbaum rosswoodland hillssharon t rowlandschief executive officer roselandsharon t rowlandschief executive officer woodland hillsjoshua ruchnew yorkalan e salzmandirector san brunoalan e salzmandirector san brunoalan e salzmandirector san brunoalan e salzmandirector san brunogadi shamiasvp apd woodland hillsrobert k spitzwoodland hillsrobert k spitzwoodland hillspower stevenwoodland hillsedward thompsondirector woodland hillsvantagepoint management incsan brunovantagepoint management incwoodland hillsvantagepoint management incsan brunovantagepoint venture associates 0 llcsan brunovantagepoint venture associates 0 llcsan brunovantagepoint venture associates iii llcsan brunovantagepoint venture associates iii llcsan brunovantagepoint venture associates iv llcsan brunovantagepoint venture associates iv llcsan brunovantagepoint venture associates iv llcsan brunoventure partners 0qlp vantagepointsan brunovantagepoint venture partners iii lpsan brunovantagepoint venture partners iii lpsan brunovantagepoint venture partners iii q l psan brunovantagepoint venture partners iii q l psan brunovantagepoint venture partners iv lpsan brunovantagepoint venture partners iv lpsan brunovantagepoint venture partners iv principals fund lpsan brunovantagepoint venture partners iv principals fund lpsan brunovantagepoint venture partners iv principals fund lpsan brunovantagepoint venture partners iv q lpsan brunovantagepoint venture partners iv q lpsan brunoadam f wergelesgeneral counsel secretary woodland hillsadam f wergelesgeneral counsel secretary woodland hillsadam f wergeleschief legal officer secretary woodland hillsjason whittsan brunorobert wrightevp  gen man reachlocal exc woodland hillsrobert wrightevp  gen man reachlocal exc woodland hillsrobert wrightevp  gen man reachlocal exc woodland hillsgordon zorikwoodland hillsgordon zorikwoodland hillspersons related to mark leschly  nephrogenex incnamepositioncitycare capital iii llcdirector princetoncare capital investments iii lpprincetoncare capital offshore investments iii lpprincetonramsay davidprincetonsteiner eugenprincetonsteiner eugenraleighj wesley foxpres  chief sci officer research triangle parkj wesley foxpres  chief sci officer raleighjohn hamillchief financial officer bridgewaterjohn hamillchief financial officer research triangle parkjohn hamillchief financial officer raleighfox jprincetonpatel jaikrishnaraleighmitchum jamesraleighhamill johnraleighhabib kairouznew yorkpierre legaultchief executive officer berkeley heightspierre legaultchief executive officer raleighpierre legaultresearch triangle parkpierre legaultchief executive officer research triangle parkmark leschlynew yorktaglietti marcoraleighleschly markprincetonrichard j markhamdirector princetonrichard j markhamdirector research triangle parkjames p mitchumdirector research triangle parkjaikrishna patelchief medical officer raleighbob petersonvp of prod dev  reg affs research triangle parkbob petersonvp of prod dev  reg affs raleighlegault pierreraleighrho capital partners llcnew yorkrho ventures v affiliates llcnew yorkrho ventures v lp0 owner new yorkmarkham richardprincetonmarkham richardraleighrmv v llcnew yorkseltzer robertraleighjoshua ruchnew yorkrobert r seltzerdirector research triangle parkeugen steinerdirector stockholmeugen steinerdirector research triangle parkmarco tagliettidirector new yorkmarco tagliettidirector research triangle parkmartin vogelbaumdirector research triangle park potentially same personnamecitycountryleschly markpalo altocaleschly markpalo altocaleschly marknew yorknyleschly markrichardsontxleschly markprincetonnhleschly markpalo altocaleschly marknew yorknyleschly markcampbellcaleschly markpalo altocaleschly markel segundocaleschly markcampbellcaleschly marksanta monicacaleschly markpalo altocaleschly marksan diegoca mark leschly — iconica partners mark leschly mark leschly is a managing director of iconica partners and a managing partner and owner of rho capital partners a venture capital and growth equity firm with over b of assets under managementfor over twenty years mark has helped entrepreneurs and companies achieve excellent outcomes by providing strategic operational and financial guidance as a founder investor executive and board member  he has a strong track record helping entrepreneurs succeed in building compelling high growth businesses  his impact and successes have ranged broadly from healthcare to technology digital media ecommerce and mobile sectors to sports media and entertainment and he has been involved in building several billion dollar businesses  he also has extensive experience and success with mergers ipos and acquisitions during his careermark currently serves on the board of the directors of numerous public and private companies across the sports media technology and healthcare sectors including mandalay sports media msm a leading production and media company focused on creating world class sports content fuse the largest independent cable network distributed in over 0m us homes with a focus on music and multicultural millennial audiences justfab a leading multibrand fashion subscription ecommerce company greenfly a technology platform and engagement solution for media enterprises to create manage and share short form video content with their network relationships chargepoint a leading network software and infrastructure provider for electric vehicle charging and tapjoy a leading mobile advertising and app monetization platformmark is a former touring atp professional tennis player previously selected to the danish davis cup team  he is an advisory member of both usta player development and the usta foundation he is a minority owner in the los angeles football club a major league soccer mls team and the oklahoma city dodgers a aaa minor league baseball team  mark also currently serves on the board of directors of the national venture capital association and was chairman of venturescape  the industry’s annual meeting and conference previously he was president of jennifer lopez enterprises and a general partner at healthcare ventures a leading life sciences venture capital firm and a strategic management consultant at mckinsey  company  he received an mba from stanford university’s graduate school of business and a ba with honors from harvard university jan leschly  wikipedia jan leschly from wikipedia the free encyclopedia jump to navigation search jan leschly country sports  denmark born 00  september 0 age  jutland denmark plays lefthanded singles highest ranking no 0  lance tingay grand slam singles results french open r  wimbledon r  us open sf  doubles grand slam doubles results french open r  wimbledon qf  mixed doubles grand slam mixed doubles results wimbledon r  0  jan leschly born  september 0 is a danish businessman and former professional tennis player leschly has been the chairman and chief executive officer of care capital llc a private equity firm since may 00 he was a tour tennis professional in the 0s and early 0s between  and  he participated in nine wimbledon championships and achieved his best result in  when he reached the fourth round of the singles event and partnering with his countryman jørgen ulrich uncle of lars ulrich whose father is torben ulrich the quarterfinals of the doubles event jan leschly was in the semifinal of the us championship at forest hills in  where he lost to clark graebner in five sets he was ranked world no 0 for  in lance tingay amateur rankings for the daily telegraph other positions chief executive and director smithkline beecham a company that develops and markets pharmaceuticals and overthecounter medicines  to may 00 director american express viacom maersk and dynavax technologies corporation member advisory board of daimler chrysler and the emory university business school deans advisory council career finalsedit outcome no date championship surface opponent score runnerup  march  johannesburg south africa hard manuel santana – – – – – runnerup   february  philadelphia united states carpet i manuel santana – – runnerup   july  båstad sweden clay ilie năstase – – – – referencesedit  a b united states lawn tennis association  official encyclopedia of tennis first edition p   wimbledon player archive – jan leschly aeltc  external linksedit jan leschly at the association of tennis professionals jan leschly at the international tennis federation jan leschly at the davis cup kubulus alumni – jan leschly at københavns universitet tennis archives v t e american express payment products accolades cards charge cards credit cards expresspay travelers cheques centurion card plum card spunoff companies ameriprise financial first data corp lehman brothers merchants despatch railway express agency warneramex satellite entertainment notable current and former executives henry wells william fargo j c fargo howard l clark sr ralph reed james d robinson iii louis v gerstner jr sanford i weill harvey golub kenneth chenault gary crittenden corporate directors kenneth chenault chairman daniel akerson charlene barshefsky ursula burns peter chernin vernon jordan jr jan leschly rick levin edward d miller frank popoff robert d walter ron williams other the adventures of seinfeld  superman american express incentive services salad oil scandal world monuments watch  broadway falmer stadium the american express community stadium small business saturday three world financial center this danish biographical article is a stub you can help wikipedia by expanding it v t e retrieved from httpsenwikipediaorgwindexphptitlejanleschlyoldid categories 0 birthsamerican expressdanish businesspeopledanish male tennis playersliving peopleprivate equity and venture capital investorsdanish people stubshidden categories place of birth missing living peopleall stub articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages العربيةdanskفارسیfrançaissrpskohrvatski  српскохрватски edit links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view a new york vc spotlight mark leschly  alleywatch skip to primary navigation skip to content skip to primary sidebar skip to footeralleywatchthe pulse of nyc startups and techheader right main navigationa new york vc spotlight mark leschlyjuly   by dan kauffman0sharesfacebooktwittersubscribegooglewhatsapppinterestdiggstumbleuponvkdeliciousbufferweibopocketmark leschly has over  years experience as a venture capitalist investing in the healthcare media and information technology sectorsleschly is presently a managing partner with rho capital partners an investment and venture capital management company that focuses on energy technology new media healthcare information technology and communications he is also a member of rho ventures and the investment committee of rho fund investors leschly has founded and financed a number of emerging private companies while establishing and managing rho’s west coast investment officeprior to joining rho in  leschly spent five years as a general partner with healthcare ventures another venture capital management company and spent several years in management consulting with mckinsey  companyto list just another one of his many astounding accomplishments leschly was also a touring professional tennis player previously selected to the danish davis cup teamhe received his ba from harvard university and his mba from stanford university’s graduate school of businessvc firmrho capital partners inc – managing partner healthcare ventures lp – general partner mckinsey  company – management consultingsector focushealthcare new media digital media internet mobile information technologyselected investmentsactive power capstone turbine ciena compaq computer gloucester pharmaceuticals human genome sciences ivillage medimmune reachlocal shire pharmaceuticals tacodaboards anacor pharmaceutical archemix broadlogic network technologies gloucester pharmaceuticals chargepoint inotek pharmaceuticals memory pharmaceuticals mpv nitromed orametrix orqis medical ripe digital media senomyx sitv slacker tercica tolerx vanda pharmaceuticals verenium vicuron pharmaceuticalsexpertise areas healthcare life sciences medical devices information technology energy digital media internet investing private equity venture capital mobile managementwebsite  social medialinkedin company websitememorable quoteson coulomb technologies inc installing electric car charging stations in multiple cities “coulomb continues to make great strides as an emerging leader in the ev infrastructure space they are quickly expanding their footprint and building a compelling sustainable business”on netshelter technology media “netshelter is a leader in technology media by helping the industry’s most recognized brands harness the power of a highly influential network of tech publishers and audiences”share on twittershare on linkedin primary sidebar footer ad area footerabout alleywatchabout us advertise legal privacy terms of usecontactcontact us advertise tips write for uschannelsnyc venture capital nyc tech events nyc tech news nyc startups nyc coworkingsocialfacebook twitter linkedin instagram pinterestcontactcontact us advertise tips write for ussubscribe email address 0sharesfacebooktwitter you are seconds away from signing up for the hottest list in new york tech join the millions and keep up with the stories shaping entrepreneurship sign up today subscribe nowclose this popup previous my investment thesis next navigating facebook’s faceliftspast present and future leadership  bluebird bio toggle navigation our company leadership collaborations our focus overview severe diseases cancer immunotherapy gene editing publications patients  families gene therapy adrenoleukodystrophy βthalassemia sickle cell disease medical professionals become a bluebird overview join the nest investors  media toggle navigation our company leadership collaborations our focus overview severe diseases cancer immunotherapy gene editing publications patients  families gene therapy adrenoleukodystrophy βthalassemia sickle cell disease medical professionals become a bluebird overview join the nest investors  media our company we are committed to our vision of transforming lives and making hope a reality for patients with severe genetic and rare diseases and with cancer   leadership derek adams phd chief technology and manufacturing officer jason f cole esq chief legal officer david davidson md chief medical officer alison finger head of commercial philip d gregory d phil chief scientific officer susanna high chief operating officer nick leschly chief bluebird andrew obenshain head of europe manisha pai senior director investor relations  corporate communications joanne smithfarrell phd senior vice president corporate development and strategy jeffrey t walsh chief financial and strategy officer kathy wilkinson chief people officer board of directors daniel s lynch – chairman independent john o agwunobi md chief health and nutrition officer at herbalife nutrition institute wendy l dixon phd formerly of bristolmyers squibb company nick leschly chief bluebird james mandell md formerly ceo of boston childrens hospital john m maraganore phd alnylam pharmaceuticals douglas a melton phd xander university professor at harvard university david p schenkein md agios pharmaceuticals mark vachon formerly of general electric derek adams phd chief technology and manufacturing officer derek adams joined us in march  as our chief technology and manufacturing officer prior to joining bluebird derek was the senior vice president of cmc at evelo biosciences at evelo derek established the initial process development function and supply chain for clinical studies and drove strategy for product development prior to his time at evelo he served as vice president of technical and strategic product development at alexion pharmaceuticals where his responsibilities included developing and supporting all manufacturing processes globally as well as global clinical supply chain  his alexion career also included roles as plant manager for alexion’s rhode island manufacturing facility and head of upstream process development  derek began his career in process technical support for live virus vaccine production at merck  co inc derek holds a phd in chemical engineering from the university of minnesota and a bs in chemical engineering with high distinction from worcester polytechnic institute wpi daniel s lynch – chairman independent daniel s lynch has served as chairman of our board of directors since may  when he joined third rock ventures as an entrepreneurinresidence since october 0 mr lynch has advised and served as executive chair or member of the board of directors for a number of private biopharmaceutical companies including stromedix inc until its acquisition by biogen idec in february  avila therapeutics inc until its acquisition by celgene corporation in february  rana therapeutics inc nimbus discovery llc edimer pharmaceuticals ember therapeutics inc and blueprint medicines inc he serves on the board of directors of bind biosciences inc and eleven biotherapeutics inc previously mr lynch served as chief executive and chief financial officer of imclone systems corporation or imclone as imclone’s chief executive officer he led imclone through a significant turnaround helping to restore the company’s reputation and to secure fda approval of erbitux cetuximab a novel cancer treatment as its chief financial officer mr lynch led negotiations to form the major partnership between imclone and bristolmyers squibb earlier in his career he served in various financial positions at bristolmyers squibb over a year tenure he served on the board of directors and the audit committee of us oncology inc for five years until december 0 when it was acquired by mckesson mr lynch received his ba in mathematics from wesleyan university and his mba from the darden graduate school of business administration at the university of virginia john o agwunobi md chief health and nutrition officer at herbalife nutrition institute john o agwunobi md has served as a member of our board of directors since june  since february  dr agwunobi has served as chief health and nutrition officer at herbalife nutrition institute responsible for training education science strategy and product development prior to joining herbalife dr agwunobi was an independent consultant advising a number of privatelyheld healthrelated companies including serving as an advisory board member of shopko stores operating co llc on behalf of the private equity firm sun capital partners from september 0 to april  dr agwunobi served as senior vice president and president of health and wellness for walmart in the united states where he grew the business and provided insight and advice on the company’s health reform position from december 0 to september 0 he served as the assistant secretary of health for the us department of health and human services where he was responsible for disease prevention and health promotion his responsibilities included the oversight of the centers for disease control national institute of health the us food and drug administration the office of the us surgeon general and numerous other public health offices and programs dr agwunobi has served on numerous boards including currently as a director at magellan health inc and at the us african development foundation dr agwunobi is a licensed physician in florida maryland and washington dc he received his medical training at the university of jos and completed his pediatric residency at howard university he also holds a master’s degree in public health from johns hopkins university and master’s in business administration from georgetown university malcolm k brenner mb phd malcolm brenner is a professor in the departments of pediatrics and medicine section of hematologyoncology at baylor college of medicine he is also director of the center for cell and gene therapy which was established by baylor college of medicine the methodist hospital and texas children’s hospital malcolm’s main research interest is in the field of tumor immunology he has compared the relative immunostimulatory and antitumor potency of autologous and allogeneic tumor vaccines in children with advanced neuroblastoma and in adults with acute and chronic leukemia recipients of both autologous and allogeneic vaccines showed evidence of local immunity but the autologous vaccine showed more potent systemic activity similar studies are also underway in patients with acute and chronic leukemia his laboratory is also using molecular techniques to increase the effectiveness of cytotoxic t cell killing of tumor cells malcolm is an associate editor of blood and of molecular therapy and he is the principal investigator or coinvestigator on five national institutes of health grants malcolm earned his phd mbchb and ba from cambridge university in england he completed a fellowship at the royal college of pathologists and the royal college of physicians jason f cole esq chief legal officer jason cole has served as our chief legal officer since march  after serving as our senior vice president general counsel for two years prior to joining us jason served as executive vice president corporate development and general counsel at zalicus inc from september  through march  and as senior vice president general counsel of zalicus and its predecessor company combinatorx inc from january 0 to september  from  to 0 jason was a corporate and securities attorney at ropes  gray llp mr cole holds an ab in government from dartmouth college and a jd from columbia university school of law david davidson md chief medical officer david davidson md has served as our chief medical officer since february  prior to joining us dave served as a senior medical director at genzyme corporation or genzyme where he led clinical research for programs in phases i through iv across a wide range of therapeutic areas for more than a decade most recently dave was the medical leader for genzyme’s gene therapy and pompe disease enzyme replacement therapy programs in addition to dave’s translational medicine experience he has also worked on a number of commercial products including fabrazyme and myozymelumizyme and was integral in crafting the new drug application that resulted in the approval of welchol prior to genzyme dave was a medical director at geltex pharmaceuticals inc he completed clinical and research fellowships in infectious diseases at the harvard longwood combined infectious diseases program and received his ba from columbia university and his md from new york university school of medicine in addition he completed an internal medicine internship residency training and an endocrinology research fellowship at the university of chicago hospitals wendy l dixon phd formerly of bristolmyers squibb company wendy l dixon phd has served as a member of our board of directors since april  in  dr dixon was a principal at great meadow consulting llc and in 0 she served as senior advisor at the monitor group since 0 dr dixon has advised and consulted and in some instances served as a member of the board of directors for a number of biopharmaceutical companies including alkermes plc incyte corporation orexigen therapeutics inc furiex pharmaceuticals inc and formerly ardea biosciences inc sold to astrazeneca plc in  and dentsply international dr dixon also served as chief marketing officer and president of global marketing for bristolmyers squibb and as a member of the ceo’s executive committee from 0 to 0 she has had an over 0year career in the pharmaceutical and biotechnology business combining a technical background and experience in drug development and regulatory affairs with commercial responsibilities in building and leading organizations and launching and growing more than  pharmaceutical products including tagamet fosamax singulair plavix abilify reyataz and baraclude from  to 0 she was senior vice president marketing at merck and prior to that she held executive management positions at west pharmaceuticals osteotech and centocor and various positions at smithkline and french now glaxosmithkline in marketing regulatory affairs project management and as a biochemist dr dixon received her bsc msc and phd from the university of cambridge uk mitchell h finer phd mitchell h finer phd served as bluebird’s chief scientific officer from march 0 to july  prior to joining us dr finer served as senior vice president of development and operations for novocell inc now viacyte inc a stem cell engineering company researching treatments for diabetes and other chronic diseases from november  through march 0 from july 0 through november  dr finer served as chief executive officer of intracel holdings llc from june  to june 0 he held the position of president and chief executive officer of genteric inc or genteric previously he had served as genteric’s chief scientific officer from november  to june  and as vice president of research and development for the gencell division of aventis pharma now sanofi from april  to november  he was also a founder and vice president of research for cell genesys inc and a founder of abgenix inc and avalanche biotechnologies inc dr finer received his ba in biochemistry and bacteriology from the university of california at berkeley and his phd in biochemistry and molecular biology from harvard university he completed a postdoctoral fellowship at the whitehead institute for biomedical research alison finger head of commercial alison finger joined us in august  as our head of commercial prior to joining bluebird alison spent  years at bristolmyers squibb bms where her career began in consumer medicines and progressed to global leadership roles in hepatitis hivaids hematology and neurodegenerative diseases she has launched global regional and national brands in hepatitis hivaids diabetes rheumatoid arthritis oncology and migrainepain and has led teams in consumer medicines us operations and global commercial alison was also responsible for building and embedding marketing capabilities throughout the company as bms’ executive sponsor for marketing excellence alison is currently a director for pm connective a not for profit established to demonstrate value of stakeholder integration in personalized medicines she holds a ba in english writing from saint lawrence university and an mba from the fuqua school of business at duke university stephen p goff phd stephen p goff is higgins professor of biochemistry and molecular biophysics and professor of microbiology at columbia university college of physicians and surgeons he is also an investigator at howard hughes medical institute stephen’s research at hhmi focuses on the retrovirus which he started studying during his postdoctoral fellowship in the massachusetts institute of technology laboratory of david baltimore he is interested in the replication of retroviruses and the cellular gene products that interact with these viruses stephen is particularly proud of his identification in 0 of the abl oncogene from the abelson virus and later of its counterpart in the normal dna of a mouse chromosome abl was one of the first oncogenes discovered stephen earned an ab in biophysics from amherst college and his phd in biochemistry from stanford university philip d gregory d phil chief scientific officer philip d gregory d phil has served as our chief scientific officer since june  philip was formerly with sangamo biosciences where he held multiple leadership positions over a nearly fifteenyear tenure most recently serving as chief scientific officer and senior vice president research in this role he was responsible for the scientific direction and strategic research planning for the company philip played an integral role in sangamo’s partnerships and drove early discovery and development for several ind candidates in multiple therapeutic areas prior to joining sangamo he was a postdoctoral fellow at ludwigmaximiliansuniversität münchen philip holds a d phil in biochemistry from oxford university keble college and a bsc in microbiology from sheffield university susanna high chief operating officer susanna high has served as chief operating officer since  prior to joining bluebird she worked at alnylam pharmaceuticals inc holding increasing responsibilities for company strategy business planning portfolio and program management alliance management information technology and broader organizational capability building initiatives prior to her time at alnylam susanna worked at millennium pharmaceuticals she received her ba in economics and business management financial from università bocconi milan italy and her mba from the massachusetts institute of technology – sloan school of management r keith humphries md phd keith humphries is distinguished scientist and director of terry fox laboratory and a professor of medicine at the university of british columbia ubc he is an associate member of pathology and laboratory medicine and medical genetics at ubc is program project group leader of the terry fox foundation of canada and director of transgenic and gene targeting facility bcca one of keith’s research focuses is directed towards the development of improved gene transfer methods to primitive hematopoietic stem cells with the goal of improving approaches for gene function studies and gene therapy this work includes a major emphasis on developing strategies for gene therapy of inherited anemias such as thalassemia and sickle cell disease novel approaches for nonviral mediated gene transfer to hemopoietic cells are also being explored by utilizing crelox recombination methodology christof von kalle md phd christof von kalle serves as a member of the scientific advisory board for bluebird bio and for gatc biotech ag he is chairman of the department of translational oncology at the german cancer research center and director of the national center for tumor diseases at the university hospital heidelberg christof is an adjunct professor of pediatrics at the cincinnati children’s hospital medical center division of experimental hematology and is a group leader in the section of hematopoiesis and gene transfer at the institute for molecular medicine and cell research at the university of freiburg he is also a senior clinical investigator of the gene therapy program and senior medical staff fellow of the department of internal medicine at the university of freiburg medical school in germany christof is worldrenowned for his research in the areas of gene therapy for human hemoglobinopathies retrovirusmediated therapy of hematopoietic stem cells and clinical hematopoietic stem cell transplantation he participated in the  french gene therapy trial that restored the immune systems of nine of  boys with xlinked severe combined immunodeficiency disease making this the first clear success in gene therapy christof received his md and phd from cologne university medical school philippe leboulch md cochair of scientific advisory board head of the institute of emerging diseases and innovative therapies of cea and inserm professor of medicine university of paris and visiting professor harvard philippe leboulch is a scientific founder of bluebird bio he serves as the cochairman of its scientific advisory board and conceived the antisickling tq globin modification used in the lentiglobin vector he is a professor of medicine and cell biology at the university of paris and visiting professor at harvard medical school philippe is also the director of the institute of emerging diseases and innovative therapies of the cea near paris and director of an inserm research unit he maintains a research laboratory in the genetics division of the brigham  women’s hospital at harvard medical school where he previously served as a fulltime faculty member for  years after a postdoctoral fellowship at mit philippe is an expert in vectorology and hematopoietic gene therapy with special emphasis on the betahemoglobinopathies he has been published extensively in highimpact journals and is a regularly invited speaker at major international conferences philippe was a member of the editorial board of blood the journal of the american society of hematology he has served on major committees of the national institutes of health and the american society of gene therapy philippe has received numerous nih grant awards and prizes that include the grand prize etancelin of the french national academy of sciences nick leschly chief bluebird nick leschly has served as our chief bluebird since september 0 formerly nick was a partner and founding member of third rock ventures in 0 nick played an integral role in the overall formation development and business strategy of several of third rock’s portfolio companies including agios pharmaceuticals inc and edimer pharmaceuticals inc prior to joining third rock he worked at millennium pharmaceuticals leading several earlystage drug development programs and served as the product leader for velcade nick also founded and served as chief executive officer of medxtend corporation he received his bs in molecular biology from princeton university and his mba from wharton business school he currently serves as a board member of the biotechnology innovation organization bio synlogic and proclara biosciences james mandell md formerly ceo of boston childrens hospital dr james mandell has served as a member of our board of directors since january  dr mandell became chief executive officer of boston children’s hospital and children’s medical center on october  00 retiring from the position in october  during his tenure dr mandell was a member of the board of trustees and professor of surgery at harvard medical school prior to joining children’s he served as dean of albany medical college and professor of surgery and pediatrics dr mandell was promoted from chief of urology to dean of albany medical college in l he also served as executive vice president for health affairs at albany medical center and executive medical director of albany medical center hospital prior to his tenure at albany medical college he was a member of the medical staff at children’s hospital for nine years advancing to an associate in surgery with an associate professor appointment at harvard medical school dr mandell serves on the board of the franciscan’s hospital for children and as chair of the board of the harvard risk management company in addition to a medical degree from the university of florida college of medicine dr mandell holds a master’s in health systems management from union college new york john m maraganore phd alnylam pharmaceuticals john m maraganore phd has served as a member of our board of directors since january  since december  dr maraganore has served as the chief executive officer and as a director of alnylam pharmaceuticals inc from december  to december 0 dr maraganore served as president of alnylam from april 00 to december  dr maraganore served as senior vice president strategic product development with millennium pharmaceuticals inc before millennium he served as director of molecular biology and director of market and business development at biogen inc now biogen idec inc prior to biogen dr maraganore was a scientist at zymogenetics inc and the upjohn company dr maraganore is chairman of agios pharmaceuticals and is also a member of the immunology advisory council of harvard medical school and a member of the biotechnology industry organization board dr maraganore holds a ba in biological sciences from the university of chicago and an ms and a phd in biochemistry and molecular biology from the university of chicago douglas a melton phd xander university professor at harvard university douglas a melton phd has served as a member of our board of directors since june  dr melton is the xander university professor at harvard university where he has been a professor for over thirty years he has served as the codirector of the harvard stem cell institute since 0 and also as the cochair of the department of stem cell and regenerative biology since 0 since  dr melton has been an investigator of the howard hughes medical institute he was a scientific cofounder of gilead sciences inc curis inc and semma therapeutics inc dr melton received a bs in biology from the university of illinois a ba in history and philosophy of science at cambridge university and received his phd in molecular biology at trinity college at cambridge and the mrc laboratory of molecular biology andrew obenshain head of europe andrew obenshain has served as head of europe since  he was most recently at shire in paris france where he was the general manager of france and benelux overseeing a portfolio including seven rare disease products prior to shire andrew spent eight years at genzyme and sanofi holding roles of increasing responsibility in business development marketing and global commercial operations mr obenshain received his mba from northwestern university’s kellogg school of management and his ba in genetics cell and developmental biology from dartmouth college manisha pai senior director investor relations  corporate communications manisha joined bluebird in may  as senior director investor relations  corporate communications prior to coming to bluebird she served as the head of investor relations and corporate communications at epizyme inc where she was responsible for investor relations public relations patient advocacy and employee communications manisha has also held communications leadership positions at pharmacyclics inc where she led communications for the launch of imbruvica® ibrutinib and millennium the takeda oncology company where she oversaw global and us public relations for the oncology franchise manisha received an ab in english literature from amherst college philip reilly md jd phil reilly is a venture partner at third rock ventures in boston mass he joined third rock in 0 and supports the firm’s founding and advancement of new ventures with a particular focus on nurturing and growing transformational companies dedicated to breakthrough treatments for genetic disorders phil is an accomplished entrepreneur and has a longstanding interest in genetic testing and developing new therapies for genetic diseases he served as interim chief medical officer of bluebird bio in 0 and previously served on the board of directors of the american society for human genetics phil is currently a trustee of cornell university and is a founding fellow of the american college of medical genetics in 00 and  he served as president of the american society of law medicine and ethics phil has held numerous teaching positions at tufts university school of medicine harvard medical school and cornell university as well as adjunct professor of both legal studies and biology at brandeis university he currently serves on the board of edimer pharmaceuticals phil holds an md from yale university and a jd from columbia university he is a member of the massachusetts bar and is board certified in internal medicine and clinical genetics andrew m scharenberg md andrew m scharenberg is a professor of pediatrics adjunct in immunology at the university of washington school of medicine and codirector of the program for cell and gene therapy at seattle children’s hospital andrew’s laboratory at seattle children’s has been at the forefront of developing and translating technologies for gene editing and gene repair he and his colleagues developed the megatal monomeric nuclease platform and have pioneered the coexpression of accessory factors with nucleases for controlling the processing of nucleaseinduced dna double strand breaks his laboratory is now focused on refining and translating gene editing technologies for treating human hematopoietic genetic disease andrew earned a bs in biochemistry from indiana university and an md from the university of north carolina school of medicine he is principal investigator on numerous nih grants including past principal investigator and codirector of the northwest genome engineering consortium and also past cofounder of pregenen a pioneering gene editing biotechnology company acquired by bluebird bio in  david p schenkein md agios pharmaceuticals david p schenkein md has served as a member of our board of directors since april  since august 0 dr schenkein has served as the chief executive officer of agios pharmaceuticals from april 0 to july 0 dr schenkein served as senior vice president of oncology development and genentech dr schenkein is also a director for agios pharmaceuticals foundation medicine and blueprint medicines dr schenkein received his ba in chemistry from wesleyan university and his md from upstate medical school joanne smithfarrell phd senior vice president corporate development and strategy joanne smithfarrell joined us in april  as our senior vice president corporate development and strategy prior to joining bluebird joanne was vice president business development transactions at merck inc at merck joanne led the team that structured negotiated and executed business development transactions supporting merck research labs prior to merck she was vice president of strategic transactions at pfizer inc joanne holds a phd in physics from the catholic university of america and a bs in physics and mathematics from vanderbilt university she was also a fellow in biomedical  chemical engineering at the harvardmit division for health science  technology dr robert langer’s lab where she received the nih national service award in research mark vachon formerly of general electric mark vachon has served as a member of our board of directors since july  mr vachon has assumed a variety of leadership positions across the general electric organization over 0 years and was a company officer since  mr vachon was president and ceo of ge healthcare americas from 0 to 0 and prior to that he was president and ceo of global diagnostic imaging ge healthcare between 0 and 0 between  and 0 mr vachon was executive vice president and cfo at ge healthcare currently mr vachon is leading an environmentally focused initiative by ge as vice president of ecomagination mr vachon serves on the board of northeastern university mr vachon holds a bs in finance from northeastern university jeffrey t walsh chief financial and strategy officer jeff walsh has served as our chief operating bluebird since may  jeff has  years of experience in executive leadership positions with responsibility for finance business development commercial and business operations strategic planning and legal functions with established and emerging public and private life sciences companies from november  to february  jeff served as chief business officer of taligen therapeutics inc where he played a key role in the growth of the company and the ultimate sale of taligen therapeutics inc to alexion pharmaceuticals inc in january  jeff started his career at smithkline beecham corporation in finance and worldwide business development roles he subsequently held senior business development finance sales and operations roles at pathogenesis corp pgns acquired by chiron corporation allscripts healthcare solutions inc exact sciences corporation and inotek pharmaceuticals corp jeff received his ba in sociology and economics from yale university and his mba from the kellogg graduate school of management at northwestern university kathy wilkinson chief people officer kathy wilkinson joined us in  as a senior director of human resources and since joining us she has overseen our growth from  employees to over 00 while building and fostering a culture we love – passionate fun and relentlessly focused on patients and our people she leads all human resource functions including staffing and recruitment strategies leadership development and learning organizational design and compensation and talent engagement approaches and practices prior to bluebird kathy held leadership roles in human resources at adnexus codon devices and aspect software kathy holds a ba in sociology from harvard university this site implements cookies to improve your experience find out moreokay